TOKYO (Reuters): Japanese pharmaceuticals company KM Biologics Co has already seen overseas interest in its monkeypox vaccine which was recently approved by domestic regulators.
KM Biologics, a unit of candy maker Meiji Holdings Co, has had "several inquiries from overseas" a company official told Reuters on Wednesday (Aug 3), declining to comment on any export plan for the shot.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
